Russian Federation coronavirus vaccine trial: Candidates safe and elicit antibody response

Sunday, 06 Sep, 2020

And in Phase 3, countries with higher transmission rates are initially prioritised, but all countries should eventually receive sufficient vaccines to halt transmission - which is projected to require that 60 to 70 per cent of the population be immune. Merck said in July it planned to start the first human study for one of its experimental vaccines by the end of September, and a second one to enter testing by the end of this year.

Note that the U.S. authorities have allocated about $ 12 billion to develop a vaccine against coronavirus.

Alexey Shebarshin, who admitted that he is a non-scientist, said he was in the Federal Ministry of Health to formally hand over the Russian-made Vaccine against COVID-19 to Nigeria with an aide memoir which explains the details for Nigerian teams to study and get ready for further researches, patronage and application. "The next steps in all of these preliminary trials is to study the vaccine in larger patient populations who are naturally being exposed to COVID-19 in their environment", he added. The Fair Priority Model addresses these values by focusing on mitigating three types of harms caused by Covid-19: Death and permanent organ damage, indirect health consequences, such as health care system strain and stress, as well as economic destruction.

The World Health Organization (WHO) has moved to secure an initial 230 million doses of Covid-19 vaccines for Africa, while also advocating that any vaccine in development should also be tested on the continent.

Lead author Dr Denis Logunov, of the N F Gamaleya National Research Centre for Epidemiology and Microbiology in Russian Federation, said: "When adenovirus vaccines enter people's cells, they deliver the SARS-CoV-2 spike protein genetic code, which causes cells to produce the spike protein". He has publicly committed to vet any vaccine approval through an advisory committee of outside experts, who typically review clinical trial data before a vaccine is approved.

While the federal government has pledged to deliver 300 million doses by January 2021, the FDA has said it won't approve a shot for coronavirus unless there is evidence showing it is 50% effective compared with a placebo.

In a separate appearance Friday, the president said pharmaceutical companies had told him that "if this was a more typical kind of president, getting these approvals would take two or three years".

Dr Adepimpe Adebiyi wey be Director Hospital Services Department tok say dis na opportunity to expand our vaccine production. "I want to reiterate my commitment that we are putting science and the interest of society at the heart of our work", he said.